Analyst Ratings For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Today, Cowen reiterated its Outperform rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a price target of $120.00.
There are 12 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is Buy with a consensus target price of $124.5882 per share, a potential 67.50% upside.
Some recent analyst ratings include
- 8/7/2019-Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its Outperform rating reiterated by Cowen with a $120.00 price target
- 5/23/2019-Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its Neutral ➝ Neutral rating reiterated by Goldman Sachs Group with a $80.00 price target
- 4/11/2019-Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has coverage initiated with a Outperform rating and $120.00 price target
- On 5/15/2019 John Maraganore, CEO, sold 49,457 with an average share price of $70.00 per share and the total transaction amounting to $3,461,990.00.
- On 4/15/2019 Philip A Sharp, Director, sold 15,000 with an average share price of $88.23 per share and the total transaction amounting to $1,323,450.00.
- On 8/30/2018 Yvonne Greenstreet, COO, sold 2,500 with an average share price of $120.00 per share and the total transaction amounting to $300,000.00.
- On 7/25/2018 John Maraganore, CEO, sold 50,000 with an average share price of $105.39 per share and the total transaction amounting to $5,269,500.00.
- On 6/20/2018 Laurie Keating, SVP, sold 1,563 with an average share price of $105.04 per share and the total transaction amounting to $164,177.52.
- On 3/26/2018 Yvonne Greenstreet, COO, sold 7,221 with an average share price of $136.54 per share and the total transaction amounting to $985,955.34.
- On 3/20/2018 Laurie Keating, SVP, sold 1,562 with an average share price of $149.83 per share and the total transaction amounting to $234,034.46.
About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Read More…
Recent Trading Activity for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Shares of Alnylam Pharmaceuticals, Inc. closed the previous trading session at 74.38 up +2.97 4.16% with 70 shares trading hands.
